Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
12541
-
12542
-
12543
-
12544
A R13A point mutation in C4 attenuates CLCuMuV infection.
Published 2018“…<i>eIF4α</i> was used as an internal control. Values represent means ± SE from three independent experiments. <b>(C)</b> The mutant CLCuMuV carrying C4<sup>R13A</sup> (CLCuMuV-C4<sup>R13A</sup>), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”
-
12545
-
12546
-
12547
-
12548
CD44v6 is required for the growth of BTSC in CD44<sup>high</sup> GBM.
Published 2011“…B: Treatment with siRNA decreased the expression of CD44v6 in both neurosphere (left panel) and serum-propagated CD44<sup>high</sup> GBM (middle panel). …”
-
12549
-
12550
-
12551
Spatial expression pattern of proBcMF26a: GUS-GFP.
Published 2015“…<p>(A–L) Histochemical GUS assays of the T<sub>2</sub><i>Arabidopsis</i> transformed with pBGWFS7.0–proBcMF26a: GUS-GFP vector. …”
-
12552
-
12553
-
12554
Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing
Published 2010“…We report here the engineering and recovery of nsp14-ExoN mutant viruses of severe acute respiratory syndrome coronavirus (SARS-CoV) that have stable growth defects and demonstrate a 21-fold increase in mutation frequency during replication in culture. …”
-
12555
The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates
Published 2015“…Following exposure to LD<sub>50-70/40</sub> of radiation, injection of efficacious doses of entolimod administered as late as 25 hours thereafter reduced the risk of mortality 2-3-fold, providing a statistically significant (P<0.01) absolute survival advantage of 40–60% compared to vehicle treatment. …”
-
12556
-
12557
-
12558
-
12559
-
12560